Uveal melanoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
==Medical Therapy== | ==Medical Therapy== | ||
Pharmacologic medical [[therapy]] is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] disease: | Pharmacologic medical [[therapy]] is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] disease:<ref name="pmid29497459">{{cite journal |vauthors=Yang J, Manson DK, Marr BP, Carvajal RD |title=Treatment of uveal melanoma: where are we now? |journal=Ther Adv Med Oncol |volume=10 |issue= |pages=1758834018757175 |date=2018 |pmid=29497459 |pmc=5824910 |doi=10.1177/1758834018757175 |url=}}</ref> | ||
*[[Chemotherapy]] | *[[Chemotherapy]] |
Revision as of 03:24, 16 August 2019
Uveal melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Uveal melanoma medical therapy On the Web |
American Roentgen Ray Society Images of Uveal melanoma medical therapy |
Risk calculators and risk factors for Uveal melanoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]
Overview
Pharmacologic medical therapy is recommended among patients with metastatic disease and include chemotherapy, immunotherapy, and targeted therapy.
Medical Therapy
Pharmacologic medical therapy is recommended among patients with metastatic disease:[1]
- Chemotherapy
- Immunotherapy
- Checkpoint blockade
- Pembrolizumab
- Ipilimumab + nivolumab
- Ipilimumab + nivolumab
- Ipilimumab + radioembolization
- Ipilimumab + nivolumab +radioembolization
- TILs (tumor-infiltrating lymphocytes)
- T cell redirection
- Antibody–drug conjugate
- Glembatumumab vedotin
- Checkpoint blockade
- Targeted therapy
- PKC (protein kinase C)/ MEK
- AEB071 + BYL719
- Intermittent selumetinib
- Selumetinib +/– paclitaxel
- Binimetinib + AEB071
- Multi-kinase inhibition
- Sorafenib (STREAM)
- Cabozantinib versus temozolomide/ dacarbazine
- Epigenetic therapy
- HDAC (histone deacetylase) inhibition
- Vorinostat
- Pembrolizumab + entinostat (PEMDAC)
- BET (bromodomain and extra-terminal motif) inhibition
- HDAC (histone deacetylase) inhibition
- Liver-directed therapy
- IHP (isolated hepatic perfusion)
- PHP (
- PKC (protein kinase C)/ MEK
References
- ↑ Yang J, Manson DK, Marr BP, Carvajal RD (2018). "Treatment of uveal melanoma: where are we now?". Ther Adv Med Oncol. 10: 1758834018757175. doi:10.1177/1758834018757175. PMC 5824910. PMID 29497459.